A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand

Hepatology

Volumn 48, Issue 4, 2008, Pages 1062-1069

  Matthews, Gail V ^a   Avihingsanon, Anchalee ^b   Lewin, Sharon R ^c,d   Amin, Janaki ^a   Rerknimitr, Rungsun ^e   Petcharapirat, Panusit ^e   Marks, Pip ^a   Sasadeusz, Joe ^f   Cooper, David A ^a   Bowden, Scott ^g   Locarnini, Stephen ^g   Ruxrungtham, Kiat ^b,e   Dore, Gregory J ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^c ALFRED HOSPITAL   (Australia)

^d MONASH UNIVERSITY   (Australia)

^e CHULALONGKORN UNIVERSITY   (Thailand)

^f ROYAL MELBOURNE HOSPITAL   (Australia)

^g VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; TENOFOVIR DISOPROXIL; VIRUS DNA; ZIDOVUDINE; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZOXAZINE DERIVATIVE; DRUG DERIVATIVE; PHOSPHONIC ACID DERIVATIVE; TENOFOVIR;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECOMPENSATED LIVER CIRRHOSIS; DRUG RESPONSE; FEMALE; HEPATITIS B; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER DYSFUNCTION; LIVER FAILURE; MALE; MIXED INFECTION; MONOTHERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THAILAND; BLOOD; DOSE RESPONSE; DRUG COMBINATION; ETHNOLOGY; GENETICS; HEPATITIS B VIRUS; MIDDLE AGED; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ADENINE; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BENZOXAZINES; DNA, VIRAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HIV INFECTIONS; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; PROSPECTIVE STUDIES; THAILAND; TREATMENT OUTCOME; ZIDOVUDINE;

EID: 54449097612     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.22462     Document Type: Article

References (32)

1. Konopnicki D, Mocroft A, de Wit S, Antunes F, Ledergerber B, Katlama C, et al. Hepatitis B and HIV: Prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the Euro-SIDA cohort. AIDS 2005;19:593-601.
2. Thio CL, Seaberg EC, Skolasky R Jr, Phair J, Visscher B, Munoz A, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002;360:1921-1926.
3. Puoti M, Bruno R, Soriano V, Donato F, Gaeta GB, Quinzan GP, et al. Hepatocellular carcinoma in HIV-infected patients: Epidemiological features, clinical presentation and outcome. AIDS 2004;18:2285-2293.
4. Salmon-Ceron D, Lewden C, Morlat P, Bevilacqua S, Jougla E, Bonnet F, et al. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. J Hepatol 2005;42:799-805.
5. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000;283:74-80.
6. Drake A, Mijch A, Sasadeusz J. Immune reconstitution hepatitis in HIV and hepatitis B coinfection, despite lamivudine therapy as part of HAART. Clin Infect Dis 2004;39:129-132.
7. Chongsrisawat V, Yoocharoen P, Theamboonlers A, Tharmaphornpilas P, Warinsathien P, Sinlaparatsamee S, et al. Hepatitis B seroprevalence in Thailand: 12 years after hepatitis B vaccine integration into the national expanded programme on immunization. Trop Med Int Health 2006;11: 1496-1502.
8. Sungkanuparph S, Vibhagool A, Manosuthi W, Kiertiburanakul S, Atamasirikul K, Aumkhyan A, et al. Prevalence of hepatitis B virus and hepatitis C virus co-infection with human immunodeficiency virus in Thai patients: A tertiary-care-based study. J Med Assoc Thai 2004;87:1349-1354.
9. Lok AS, McMahon BJ. Chronic hepatitis B. HEPATOLOGY 2007;45:507-539.
10. Brook MG, Gilson R, Wilkins E. BHIVA guidelines on HIV and chronic hepatitis: Coinfection with HIV and hepatitis B virus infection. HIV Med 2005;6(Suppl 2):84-95.
11. Soriano V, Puoti M, Bonacini M, Brook G, Cargnel A, Rockstroh J, et al. Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel. AIDS 2005;19:221-240.
12. Matthews GV, Bartholomeusz A, Locarnini S, Ayres A, Sasaduesz J, Seaberg E, et al. Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy. AIDS 2006;20:863-870.
13. Nunez M, Perez-Olmeda M, Diaz B, Rios P, Gonzalez-Lahoz J, Soriano V. Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudine. AIDS 2002;16: 2352-2354.
14. Nelson M, Portsmouth S, Stebbing J, Atkins M, Barr A, Matthews G, et al. An open-label study of tenofovir in HIV-1 and hepatitis B virus co-infected individuals. AIDS 2003;17:F7-F10.
15. Dore GJ, Cooper DA, Pozniak AL, DeJesus E, Zhong L, Miller MD, et al. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus. J Infect Dis 2004;189:1185-1192.
16. Benhamou Y, Fleury H, Trimoulet P, Pellegrin I, Urbinelli R, Katlama C, et al. Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients. HEPATOLOGY 2006;43:548-555.
17. Dore GJ, Cooper DA, Barrett C, Goh LE, Thakrar B, Atkins M. Dual efficacy of lamivudine treatment in human immunodeficiency virus/ hepatitis B virus-coinfected persons in a randomized, controlled study (CAE-SAR). The CAESAR Coordinating Committee. J Infect Dis 1999;180: 607-613.
18. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006;131: 1743-1751.
19. Ayres A, Locarnini S, Bartholomeusz A. HBV genotyping and analysis for unique mutations. Methods Mol Med 2004;95:125-149.
20. Yuen LK, Ayres A, Littlejohn M, Colledge D, Edgely A, Maskill WJ, et al. SeqHepB: A sequence analysis program and relational database system for chronic hepatitis B. Antiviral Res 2007;75:64-74.
21. Theamboonlers A, Tangkijvanich P, Pramoolsinsap C, Poovorawan Y. Genotypes and subtypes of hepatitis B virus in Thailand. Southeast Asian J Trop Med Public Health 1998;29:786-791.
22. Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006;354:1001-1010.
23. Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005;352:2682-2695.
24. Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: A randomised trial. Lancet 2005;365:123-129.
25. Schmutz G, Nelson M, Lutz T, Sheldon J, Bruno R, von Boemmel F, et al. Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection. AIDS 2006;20: 1951-1954.
26. Peters MG, Andersen J, Lynch P, Liu T, Alston-Smith B, Brosgart CL, et al. Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. HEPATOLOGY 2006;44: 1110-1116.
27. Benhamou Y. Hepatitis B in the HIV-coinfected patient. J Acquir Immune Defic Syndr 2007;45(Suppl 2):S57-S65; discussion:S66-S57.
28. French MA, Price P, Stone SF. Immune restoration disease after antiretroviral therapy. AIDS 2004;18:1615-1627.
29. Boni C, Bertoletti A, Penna A, Cavalli A, Pilli M, Urbani S, et al. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest 1998;102:968-975.
30. Law WP, Duncombe CJ, Mahanontharit A, Boyd MA, Ruxrungtham K, Lange JM, et al. Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort. AIDS 2004;18:1169-1177.
31. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Bethesda, MD: Department of Health and Human Services; 2008. Available at: Http://aidsinfo.nih.gov/content.les/ adultandadolescentGI.pdf.
32. World Health Organization HIV/AIDS Programme. Antiretroviral therapy for HIV infection in adults and adolescents in resource limited settings: towards universal access. Geneva, Switzerland; 2006. Available at: Http://www.who.int/hiv/pub/guidelines/artadultguidelines.pdf. Accessed June 2008.